alzchem
group

AGILE SCIENCE PURE RESULTS

Q2
2026

alzchem group

ANDREAS NIEDERMAIER, CEO
ANDREAS LÖSLER, CFO

July 30, 2026

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

I. Executive Summary

II. Business and financial details

III. Back-Up

HIGHLIGHTS

Successful first half 2026 – all KPIs above prior year and on expected level

Strong performance on group level:

+ 6% revenue growth

+ 14% EBITDA growth

Refurbishment of carbide furnace on finishing line

Volume and price growth in Specialty Chemicals

Stable development in Basics & Intermediates

Phased commissioning of new nitroguanidine plant in Germany has started successfully

EUR 100m new growth financing with banks

Outlook confirmed

Sales and EBITDA on expected growth path

USA EXPANSION @ BUSHY PARK

Alzchem Establishes Nitroguanidine Production in the US

Key highlights

- Strategic site decision: Bushy Park (Berkeley County, South Carolina)
- Long term lease contract
- Supported by US government grant and state-level incentives

Project status

- ✓ Site selection completed (key milestone achieved)
- ✓ Engineering and detailed costing initiated
- Contract finalization with US government ongoing
- Planned construction start: 2027
- Planned production start: 2029

Two-pillar production strategy

Production of key raw materials

↓

Nitroguanidine production plant

Ensures:
Supply chain resilience

Strengthened regional presence

Why Bushy Park?

- Well established chemical park with existing modern infrastructure
- Access to utilities, industrial services and skilled workforce
- Strong logistics (incl. Port of Charleston)
- Support from state and local authorities
- Space to grow

© Bushy Park

AGENDA – ANALYST PRESENTATION Q2 2026

I. Executive Summary

II. **Business and financial details**

III. Back-Up

NITRALZ®

Perlka® CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES

The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)

Sales and EBITDA development on expected level with one-offs









SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	+ 11.5%	- 2.2%
Price	- 2.1%	- 1.0%
Currency	- 0.8%	- 0.4%

COMMENTS

- H1 revenue slightly below prior year
- Weak demand in agriculture and pharma business
- Continued aggressive price pressure from Asian competitors
- Metallurgical business showed first signs of stabilization in Q2
- EBITDA impacted by one-off furnace refurbishment
- Inventories reduced significantly after planned stock build-up in 2025



CREAMINO Dormex® Bioselect® DYHARD® Creapure®

SPECIALTY CHEMICALS

The "Specialty Chemicals" segment produces and sells high-quality specialty chemical ingredients with strong growth perspectives.

alzchem group

SPECIALTY CHEMICALS SEGMENT (in M€)

Ingredients for Specialty Applications push Sales and EBITDA









SALES ANALYSIS

	DELTA Q2	DELTA 01 - 06
Volume	+ 2.8%	+ 4.6%
Price	+ 6.5%	+ 7.4%
Currency	- 0.5%	- 1.9%

COMMENTS

- Specialty Chemicals outperformed prior year and is the expected key growth driver
- H1 revenue increased by 10% to EUR 214m, driven by higher volumes and prices
- Main growth areas: Human Nutrition, Defense and Custom Manufacturing
- EBITDA rose by 19% to EUR 64m, supported by product mix and scale effects
- EBITDA margin improved from 27.7% to 29.9%.
- Q2 stand alone confirmed the positive trend with revenue up 8.8% and EBITDA up 17% year-on-year

OTHER & HOLDING

The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

alzchem group

OTHER & HOLDING SEGMENT (in M€)

Regulated grid fees impact sales and result









COMMENTS

- H1 revenue broadly stable year-on-year with slight decline driven by lower electricity grid fee pass-throughs
- EBITDA effected by energy regulatory effects
- Q2 revenue increased slightly by 6.5%

FINANCIAL OVERVIEW

All KPI above prior year – net income follows EBITDA growth

Alzchem Group	Q2 2025	Q2 2026	qoq %	2025 1 - 6	2026 1 - 6	yoy %
SALES (in M€)	142.9	155.2	+8.7%	287.6	303.9	+5.7%
EBITDA (in M€)	29.1	32.2	+10.7%	56.5	64.5	+14.2%
EBITDA margin (in %)	20.4%	20.7%	+0.4 pp	19.6%	21.2%	+1.6 pp
Earnings per Share (in €)	1.57	1.66	+5.8%	3.01	3.43	+14.0%

- Sales increased to EUR 304m, while EBITDA margin improved from 19.6% to 21.2%
- Increased volumes and price increases as key drivers for positive sales trend
- Material expenses below prior year resulting from reduced carbide production during furnace renovation
- Higher sales portion of specialty products combined with sustained cost discipline resulted in a substantial improvement in EBITDA and EBITDA margin
- Higher depreciation and amortization charges reflect the increased level of investment activity
- Reduced financial result mainly resulting from non-cash interest impacts
- Net result and earnings per share follow strong operating performance – Increased by 14%

SALES ANALYSIS	DELTA Q2	DELTA 01 - 06
Volume	+5,1%	+2,2%
Price	+4,2%	+4,9%
Currency	-0,6%	-1,4%

BALANCE SHEET & CASHFLOW

CAPEX and new financing structure with material impact on balance sheet

Balance sheet KPIs (T€)	31.12.2025	30.06.2026	Deviation	
Balance sheet total	617,679	674,112	56,433	9.1%
Inventories	116,004	110,039	- 5,965	-5.1%
Equity	258,231	271,917	13,686	5.3%
Equity ratio	41.8%	40.3%	-1.5 pp	
Liabilities to Banks	41,118	87,990	46,872	114.0%
Cash and cash equivalents	71,720	65,695	- 6,026	-8.4%
Net financial debt (-) / asset (+)	**30,602**	**- 22,295**	**- 52,898**	**-172.9%**

Cashflow KPIs (T€)	1 - 6 2025	1 - 6 2026	Deviation	
Operating Cashflow	71,238	50,704	- 20,534	-28.8%
Investing Cashflow	- 40,495	- 81,226	- 40,730	100.6%
Free Cashflow	**30,743**	**- 30,522**	**- 61,264**	**-199.3%**
Financial Cashflow	- 27,338	24,440	51,778	189.4%
Net increase in cash	**3,404**	**- 6,082**	**- 9,486**	**-278.7%**

COMMENTS

- Increase in balance sheet total resulting from increased CAPEX
- Reduction in stock level – carbide stock reduced during furnace refurbishment
- EUR 50m debt increase after successful new bank refinancing of EUR 100m
- Customer contributions with EUR 42m lower impact on operating cash flow, but positive development of net working capital
- Investing cash flow increased significantly year-on-year driven by growth.
- Free cash flow turned negative year-on-year, driven by significantly higher growth investments despite strong operating cash flow
- Financial cashflow impacted by new financing structure and dividend payments

KPI impact of nitroguanidine expansion in total on balance sheet
in M€

Cash / Assets **67.5**

Other receivables **25.7**

93.2 Contract liabilities

OUTLOOK 2026 (in M€)

Ongoing growth in sales and EBITDA on expected level

SALES



EBITDA



COMMENTS

Outlook for 2026 confirmed

Major assumptions are still valid

- No significant impact of the Iran conflict; long-term disruption of global supply chains is not included in the outlook
- Possible cost increases shall be passed through to customers
- First quantities from new NQ-plant will be delivered in H2 2026

Sales Growth

- Growth mainly coming from ingredients in segment Specialty Chemicals
- Basics & Intermediates: Sales remain on previous year's level
- Organic growth, no acquisitions
- Accelerated sales in Q2 could lead to a modestly lower performance in Q3 2026

EBITDA Growth

- Further increase in specialty chemical sales will increase EBITDA as well
- **Impact from carbide furnace maintenance as expected**

FINANCIAL CALENDAR

Upcoming dates*

JUL 30	2026	Half-year Financial Report 2026
SEP 1	2026	COMMERZBANK and ODDO BHF Corporate Conference, Frankfurt
SEP 8	2026	Berenberg Food Ingredients & Chemicals Conference, London
SEP 23	2026	Berenberg and Goldman Sachs German Corporate Conference, Munich
SEP 24	2026	Baader Investment Conference, Munich
OCT 29	2026	Quarterly Statement 3rd Quarter 2026
NOV 23-24	2026	Deutsches Eigenkapitalforum, Frankfurt
DEC 1	2026	Berenberg European Conference, Fairmont London
DEC 10	2026	MPCM Exclusive Company Evening, Frankfurt

*subject to change

ALL DATES AT A GLANCE

Financial calender

FEEDBACK

We appreciate your feedback

Were your expectations met?

Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

Link

QR-Code

AGILE SCIENCE
PURE RESULTS

alzchem group

Investor Relations

T +49 8621 86-2888
F +49 8621 86-502888
ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q2 2026

I. Executive Summary

II. Business and financial details

III. Back-Up

KPI IMPACT OF CUSTOMER GRANTS

Timing and effects on balance sheet and P&L

KPI EFFECTS
2025/2026

- Cash / Assets ↑
- Other receivables ↑
- Equity →
- Contract liabilities ↑
- Equity ratio ↓
- Sales →
- EBITDA →

KPI EFFECTS
2027 et seq.

- Cash / Assets →
- Other receivables ↓
- Equity ↑
- Contract liabilities ↓
- Equity ratio ↑
- Sales ↑
- EBITDA ↑

EST KEY EFFECTS [1]



TOTAL EFFECTS in M€

Cash / Assets **67.5**

Other receivables **25.7**

93.2 Contract liabilities

EST CASH [2]



1) Only customer investment contribution / 2) Based on our current best estimate and ongoing negotiations

BALANCE SHEET

Alzchem Group

ALZCHEM GROUP (IN T€)	31.12.2025	30.06.2026	Deviation	
Intangible assets	3,530	3,784	255	7.2%
Tangible assets	276,980	328,868	51,887	18.7%
Investment properties				
Right of use (assets)	2,992	2,124	-867	-29.0%
Investments accounted for using the equity method				
Financials assets	6	6		
Trade receivables				
Other receivables	21,801	16,160	-5,641	-25.9%
there of Deferred tax assets for pensions provisions				
Deferred tax assets	15,711	14,871	-840	-5.3%
SUM NON-CURRENT ASSETS	**321,019**	**365,813**	**44,794**	**14.0%**
Inventories	116,004	110,039	-5,965	-5.1%
Trade receivables	73,416	95,573	22,157	30.2%
Financial assets	0	0	0	-209.9%
Other receivables	35,201	36,665	1,465	4.2%
Income tax receivables	319	327	8	2.6%
Cash and cash equivalents	71,720	65,695	-6,026	-8.4%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	**296,660**	**308,299**	**11,639**	**3.9%**
SUM ASSETS	**617,679**	**674,112**	**56,433**	**9.1%**

ALZCHEM GROUP (IN T€)	31.12.2025	30.06.2026	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	**232,111**	**245,592**	**13,480**	**5.8%**
Other comprehensive income	-12,398	-12,271	128	-1.0%
Own shares	-4,111	-4,114	-3	0.1%
SHARE TO THE SHAREHOLDERS	**256,296**	**269,897**	**13,601**	**5.3%**
Non-controlling interests	1,934	2,020	85	4.4%
SUM EQUITY	**258,231**	**271,917**	**13,686**	**5.3%**
Provisions for pensions	88,239	88,662	424	0.5%
Other provisions	18,981	20,156	1,175	6.2%
Loans	34,750	81,583	46,834	134.8%
Finance lease liabilities	1,239	499	-740	-59.7%
Trade liabilities	14		-14	-100.0%
Contract liabilities	88,099	87,119	-980	-1.1%
Other liabilities	492	702	210	42.6%
Deferred tax liabilities	8,730	9,479	749	8.6%
SUM NON-CURRENT LIABILITIES	**240,543**	**288,200**	**47,657**	**19.8%**
Other provisions	7,190	5,299	-1,891	-26.3%
Loans	6,368	6,407	38	0.6%
Finance lease liabilities	1,874	1,734	-140	-7.5%
Finance liabilities		0	0	
Trade liabilities	51,726	48,341	-3,385	-6.5%
Contract liabilities	2,433	6,033	3,600	148.0%
Other liabilities	38,340	37,448	-892	-2.3%
Income tax liabilities	10,973	8,732	-2,241	-20.4%
SUM CURRENT LIABILITIES	**118,904**	**113,994**	**-4,911**	**-4.1%**
Sum EQUITY AND LIABILITIES	**617,679**	**674,112**	**56,433**	**9.1%**

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



IN FINANCIAL STATEMENT	PENSION PROVISION 31.12.2025	SERVICE COSTS EBITDA (PERSONELL EXPENSES)	NET INTEREST COSTS FINANCIAL RESULT	PENSION PAYMENTS	PENSION REMEASURE-MENTS OCI	PENSION PROVISION 30.06.2026	DEFERRED TAX ASSETS	PENSION LIABILITY 30.06.2026
BALANCE SHEET		✓	✓	✓	✓		✓	
P&L		✓	✓				✓	
CASHFLOW				✓				

- Interest rates remained unchanged at 4.1%
- Pension payments develop as expected with 1.5 M€ - pension obligation has a long maturity with approx. 30 years payout period

INCOME STATEMENT

Alzchem Group

ALZCHEM GROUP (IN T€)	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026	Deviation (Q2)	
Revenue	144,680	142,879	137,266	137,290	148,653	155,250			12,370	9%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	11,436	3,433	624	545	4,143	-11,145			-14,578	-425%
Other income	5,263	5,006	3,806	9,266	7,339	6,038			1,032	21%
Raw materials and consumables used	-64,236	-47,293	-43,769	-42,989	-53,148	-39,986			7,306	-15%
Employee benefits expense	-41,150	-44,894	-43,245	-44,322	-44,117	-47,660			-2,766	6%
Other expense	-28,632	-30,036	-24,957	-29,494	-30,583	-30,297			-261	1%
EBITDA	**27,362**	**29,096**	**29,724**	**30,296**	**32,286**	**32,199**			**3,103**	**11%**
Depreciation expense	-6,552	-6,435	-6,655	-7,007	-6,701	-7,494			-1,059	16%
Impairment										
EBIT	**20,810**	**22,662**	**23,069**	**23,290**	**25,585**	**24,706**			**2,044**	**9%**
Investment income										
Other interest and similar income	712	626	819	1,082	381	175			-451	-72%
Other interest and similar expense	-1,278	-1,284	-1,254	-1,314	-1,330	-1,592			-307	24%
Financial result	**-567**	**-658**	**-436**	**-232**	**-948**	**-1,417**			**-759**	**115%**
Result from associates										
Result from ordinary business	**20,243**	**22,003**	**22,634**	**23,057**	**24,637**	**23,289**			**1,286**	**6%**
Taxes on income and profit	-5,607	-6,128	-6,297	-6,276	-6,636	-6,464			-337	5%
thereof income tax	-4,537	-6,330	-5,550	-6,040	-5,754	-5,741			*589*	*-9%*
thereof change from deferred taxes	-1,070	202	-748	-235	-882	-724			*-926*	*-458%*
Annual result	**14,636**	**15,876**	**16,337**	**16,782**	**18,001**	**16,825**			**949**	**6%**
thereof minority interests	43	43	43	43	43	43				
thereof shares held by shareholders	14,594	15,833	16,294	16,739	17,958	16,782			*949*	*6%*
Result per share in EUR	**1.44 €**	**1.57 €**	**1.61 €**	**1.66 €**	**1.77 €**	**1.66 €**				

INCOME STATEMENT

Alzchem Group

ALZCHEM GROUP (IN T€)	Q2 2025	Q2 2026	Deviation (QoQ)		YTD Jun.2025	YTD Jun.2026	Deviation (YoY)	
Revenue	142,879	155,250	12,370	8.7%	287,559	303,902	16,343	5.7%
Increase (+) / Decrease (-) in inventories of finished goods and work in progress	3,433	-11,145	-14,578	-424.6%	14,869	-7,002	-21,872	-147.1%
Other income	5,006	6,038	1,032	20.6%	10,269	13,378	3,108	30.3%
Raw materials and consumables used	-47,293	-39,986	7,306	-15.4%	-111,528	-93,135	18,393	-16.5%
Employee benefits expense	-44,894	-47,660	-2,766	6.2%	-86,044	-91,777	-5,734	6.7%
Other expense	-30,036	-30,297	-261	0.9%	-58,667	-60,880	-2,213	3.8%
EBITDA	**29,096**	**32,199**	**3,103**	**10.7%**	**56,459**	**64,486**	**8,027**	**14.2%**
Depreciation expense	-6,435	-7,494	-1,059	16.5%	-12,987	-14,195	-1,208	9.3%
Impairment	0	0	0		0	0	0	
EBIT	**22,662**	**24,706**	**2,044**	**9.0%**	**43,471**	**50,291**	**6,819**	**15.7%**
Investment income	0	0	0		0	0	0	
Other interest and similar income	626	175	-451	-72.0%	1,338	557	-781	-58.4%
Other interest and similar expense	-1,284	-1,592	-307	23.9%	-2,563	-2,922	-359	14.0%
Financial result	**-658**	**-1,417**	**-759**	**115.2%**	**-1,225**	**-2,365**	**-1,140**	**93.1%**
Result from associates	0	0	0		0	0	0	
Result from ordinary business	**22,003**	**23,289**	**1,286**	**5.8%**	**42,247**	**47,926**	**5,679**	**13.4%**
Taxes on income and profit	-6,128	-6,464	-337	5.5%	-11,735	-13,100	-1,366	11.6%
thereof income tax	*-6,330*	*-5,741*	*589*	*-9.3%*	*-10,867*	*-11,495*	*-628*	*5.8%*
thereof change from deferred taxes	*202*	*-724*	*-926*	*-458.2%*	*-868*	*-1,606*	*-738*	*85.0%*
Annual result	**15,876**	**16,825**	**949**	**6.0%**	**30,512**	**34,825**	**4,314**	**14.1%**
thereof minority interests	*43*	*43*	*0*	*0.0%*	*85*	*85*	*0*	*0.0%*
thereof shares held by shareholders	*15,833*	*16,782*	*949*	*6.0%*	*30,426*	*34,740*	*4,314*	*14.2%*
Result per share in EUR	**1.57 €**	**1.66 €**	**0**	**5.8%**	**3.01 €**	**3.43 €**	**0**	**14.0%**

CASHFLOW STATEMENT

Alzchem Group

CASHFLOW (IN M€)	Q2 2025	Q2 2026	1 - 6 2025	1 - 6 2026
Consolidated earnings before taxes	**22,003**	**23,289**	**42,247**	**47,926**
Depreciation on fixed and intangible assets	6,435	7,494	12,987	14,195
Decrease in pension provisions	-606	-656	-1,374	-1,488
Loss (+) / Profit (-) from the sale of non-current assets	0	-10	22	-37
Other non-cash income (-) and expenses (+)	1,997	3,138	2,268	5,462
Financial result	658	1,417	1,225	2,365
Interests & Taxes	-4,138	-8,979	-7,886	-13,998
Increase (+) / Decrease (-) Net Working Capital	-16,132	-15,473	-29,256	-12,512
Payments from customer grants		2,818	51,005	8,791
Cashflow from ongoing operations (Net cash flow)	**21,721**	**13,037**	**71,238**	**50,704**
Cash outflows for investments in fixed assets	-27,394	-44,706	-40,534	-81,305
Cash inflows from the sale of fixed assets	-1	45	39	79
Cash inflows from grants received for investments				
Cashflow from investing activity	**-27,394**	**-44,661**	**-40,495**	**-81,226**
Free cashflow	**-5,673**	**-31,624**	**30,743**	**-30,522**
Deposits (+) of bank loans long-term		80,000		80,000
Repayment (-) of bank loans long-term	-2,208	-31,583	-4,416	-33,166
Deposits (+) / Repayment (-) from short-term financing lines				
Dividend payments	-18,190	-21,260	-18,190	-21,260
Payment of reduction in leasing liabilities	-478	-478	-956	-957
Payments for the acquisition of own shares (incl. transaction costs)	-1	1,300	-3,605	
Payments for the issue of own shares		-5		-6
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	**-20,878**	**27,974**	**-27,338**	**24,440**

SEGMENT OVERVIEW BY QUARTER

Alzchem Group

SALES

SALES	2024 Q1 T€	2024 Q2 T€	2024 Q3 T€	2024 Q4 T€	2025 Q1 T€	2025 Q2 T€	2025 Q3 T€	2025 Q4 T€	2026 Q1 T€	2026 Q2 T€	2026 Q3 T€	2026 Q4 T€	Deviation PY (Q2) T€	Deviation PY (Q2) %	YTD Q2 2026 PY T€	YTD Q2 2026 Actual T€	Deviation PY (YOY) T€	Deviation PY (YOY) %
Basics & Intermediates	49,299	41,848	40,927	41,929	42,638	35,605	43,309	33,539	36,666	38,684			3,079	9%	78,244	75,350	-2,894	-4%
Specialty Chemicals	92,961	85,805	80,354	88,969	94,512	100,128	86,978	97,159	105,298	108,954			8,827	9%	194,639	214,252	19,613	10%
Other and Holding	7,804	8,538	7,656	8,142	7,530	7,146	6,979	6,592	6,689	7,611			465	7%	14,676	14,300	-376	-3%
Group Consolidation																		
Alzchem Group	**150,064**	**136,191**	**128,937**	**139,040**	**144,680**	**142,879**	**137,266**	**137,290**	**148,653**	**155,250**			**12,370**	**9%**	**287,559**	**303,902**	**16,343**	**6%**

EBITDA

EBITDA	2024 Q1 T€	2024 Q2 T€	2024 Q3 T€	2024 Q4 T€	2025 Q1 T€	2025 Q2 T€	2025 Q3 T€	2025 Q4 T€	2026 Q1 T€	2026 Q2 T€	2026 Q3 T€	2026 Q4 T€	Deviation PY (Q2) T€	Deviation PY (Q2) %	YTD Q2 2026 PY T€	YTD Q2 2026 Actual T€	Deviation PY (YOY) T€	Deviation PY (YOY) %
Basics & Intermediates	1,802	3,055	1,827	4,142	140	1,174	3,754	549	284	-304			-1,478	-126%	1,314	-20	-1,334	-101%
Specialty Chemicals	22,684	22,843	21,749	26,741	26,041	27,854	24,117	28,782	31,484	32,593			4,739	17%	53,895	64,078	10,183	19%
Other and Holding	537	849	1,114	-711	307	50	596	-287	222	-533			-584	<-1.000%	358	-312	-669	-187%
Group Consolidation	*-113*	*274*	*194*	*-1,717*	*874*	*18*	*1,257*	*1,253*	*296*	*443*			*425*	*>1.000%*	*892*	*739*	*-153*	*-17%*
Alzchem Group	**24,910**	**27,021**	**24,883**	**28,455**	**27,362**	**29,096**	**29,724**	**30,296**	**32,286**	**32,199**			**3,103**	**11%**	**56,459**	**64,486**	**8,027**	**14%**

ALZCHEM GROUP LOCATIONS

Production sites and sales companies



"VERBUND" – FULLY INTEGRATED BUSINESS MODEL

Vertically integrated production of chemical products based on the NCN chain



BENEFITS OF "VERBUND"

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

GLOBAL DEVELOPMENTS AS GROWTH DRIVERS

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A nutritional additive for poultry and pigs	Feed additive
	Creapure®	Creapure®, premium brand for creatine monohydrate as ingredient in sports & health nutrition	Food supplements
	LIVA DUR	Dietary supplement with pure creatine	Food supplements
	Creavitalis®	Creatine for health and food applications	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREAK-THRU' S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Silzot® HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder. paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for explosives and agrochemical products	Agriculture. Automotive. Defense

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries

	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	CaD®	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags. key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	NITRALZ®	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	Eminex®	Reduction of methane emissions during storage of manure	Agriculture
	Perlka®	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Klüh Catering, VIACTIV) Site services Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		

KEY SHARE DATA

Share details as of July 28, 2026

SHARES OUTSTANDING	10,176,335
LAST CLOSING PRICE	EUR 173.30
MARKET CAPITALIZATION	EUR 1,763.6 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
STOCK MARKET SEGMENT	SDAX
DESIGNATED SPONSOR	LBBW ODDO BHF SE

SHAREHOLDER STRUCTURE



As of June 2026: The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 5.8 of the Stoxx "DAX Equity Index Methodology Guide". The information is based on published notifications of major holdings. Certain reported positions may reflect bank holdings for trading or hedging purposes and are not separately presented above.